Elsa Borghi - Nanobiotix Head Discovery

All Insiders . France . 
Stock . Nanobiotix SA . Stakeholders . Insider . Elsa Borghi
NANO Stock  EUR 2.97  0.13  4.19%   

Insider

Elsa Borghi is Head Discovery of Nanobiotix SA
Phone33 1 40 26 04 70
Webhttps://www.nanobiotix.com

Nanobiotix Management Efficiency

The company has return on total asset (ROA) of (0.2916) % which means that it has lost $0.2916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9869) %, meaning that it generated substantial loss on money invested by shareholders. Nanobiotix's management efficiency ratios could be used to measure how well Nanobiotix manages its routine affairs as well as how well it operates its assets and liabilities.
Nanobiotix SA has accumulated 35.56 M in total debt with debt to equity ratio (D/E) of 144.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Nanobiotix SA has a current ratio of 3.61, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Nanobiotix until it has trouble settling it off, either with new capital or with free cash flow. So, Nanobiotix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nanobiotix SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nanobiotix to invest in growth at high rates of return. When we think about Nanobiotix's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Grard SoulaAdocia
78
Frederic MBAInnate Pharma
48
DVM MBAInnate Pharma
58
Marc BonnevilleInnate Pharma
63
Kyung NamWortmanCellectis
53
Franois RomagnInnate Pharma
59
Valrie DanaguezianAdocia
N/A
Odile BelzunceInnate Pharma
43
Jean EpinatCellectis
N/A
Valerie CrosCellectis
N/A
JeanChristophe MarcouxGenfit
46
Stefanie MagnerGenfit
42
Pascal PrigentGenfit
55
Mondher MDInnate Pharma
65
Emilie DesodtGenfit
40
Thomas BaetzGenfit
49
Jean FourniInnate Pharma
N/A
Laurent LannooGenfit
53
Olivier MBAAdocia
53
Pr StaelsGenfit
60
Pascal CaiseyGenfit
55
Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 102 people. Nanobiotix SA (NANO) is traded on Euronext Paris in France and employs 103 people.

Management Performance

Return On Equity-1.99
Return On Asset-0.29

Nanobiotix SA Leadership Team

Elected by the shareholders, the Nanobiotix's board of directors comprises two types of representatives: Nanobiotix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nanobiotix. The board's role is to monitor Nanobiotix's management team and ensure that shareholders' interests are well served. Nanobiotix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nanobiotix's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarah Gaubert, Head Department
Elsa Borghi, Head Discovery
Brandon Owens, VP Communication
Earl Bergey, CoFounder
Kathryn McNeil, VP Relations
AnneJuliette MA, Chief Board
Bart Rhijn, CFO Board
Pr Prasad, CoFounder Board
Alain Dostie, Chief Officer
Laurent Levy, Pres CoFounder

Nanobiotix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nanobiotix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.99
Return On Asset-0.29
Operating Margin(17.96) %
Current Valuation111.08 M
Shares Outstanding34.88 M
Shares Owned By Insiders3.78 %
Shares Owned By Institutions25.56 %
Price To Earning(12.17) X
Price To Book71.98 X
Price To Sales48.04 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Other Information on Investing in Nanobiotix Stock

Nanobiotix financial ratios help investors to determine whether Nanobiotix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanobiotix with respect to the benefits of owning Nanobiotix security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY